Tag Archive for: Solid Tumors

UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer

/in

UCB’s expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum’s discovery of treatments for solid tumors Ariceum’s expertise in radiopharmaceuticals and labelling technology will aid UCB’s discovery of treatments for immune-related diseases Potential to expand Ariceum’s pipeline with three new programs at discovery stage Berlin, Germany, and Brussels, Belgium, 11 […]

Read more

Gadeta announces significant progress in advancing pipeline and TEG platform development

/in

Aim is to develop gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for solid tumors Ph1/2 update on lead product GDT002 as well as nomination of second pipeline program GDT201 Utrecht, Netherlands and Boston, Mass., 15 March 2022: Gadeta B.V. (‘Gadeta’), a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for every cancer […]

Read more

Versameb to Attend Biotech Showcase 2022

/in

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that it will be attending Biotech Showcase: The Investor Conference for Innovators on 10-12 January 2022. The Versameb team will be attending virtually. Read more…

Read more